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In this report, we demonstrate that NADPH oxidase is activated by tumor necrosis factor-a (TNF-a) plus interferon-g (IFN-g) in human
monocytic cells (THP-1 cells) differentiated with phorbol ester (PMA) and that physiological concentration of 17h-estradiol inhibits NADPH
oxidase activity in THP-1 cells stimulated with TNF-a plus IFN-g. This effect is mediated by estrogen receptor based on estrogen receptor
antagonist (ICI 182, 780) that diminishes inhibition by 17h-estradiol. This inhibition is specific in 17h-estradiol because 17a-estradiol,
testosterone and progesterone do not inhibit NADPH oxidase activity. Activation of NADPH oxidase induced by TNF-a plus IFN-g is
caused by up-regulation of p47phox (cytosolic component of NADPH oxidase) expression. 17h-Estradiol prevents the up-regulation of
p47phox mRNA and protein expression. This prevention of p47phox expression depends on the inhibition of NF-nB activation. Our results
implicate that 17h-estradiol has an anti-atherosclerotic effects through the improvement of nitric oxide (NO) bioavailability caused by the
regulation of superoxide (O2
) production.
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1. Introduction
Estrogen replacement therapy in postmenopausal women
has been reported to reduce the risk of cardiovascular
disease [1]. Although estrogen replacement promotes a
more favorable lipid profile, this effect does not sufficiently
explain the total anti-atherosclerotic benefit. For example,
estrogens have been suggested to have direct protective
actions on the vasculature.
Nitric oxide (NO) excreted from endothelial cells—an
important physiological factor of vascular homeostasis—is
synthesized by endothelial nitric oxide synthase (eNOS).
The impaired NO release is associated with endothelial
dysfunction in atherosclerosis [2,3].0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0167-4889(03)00026-0
Abbreviations: PMA, phorbol 12-myristate 13-acetate; TNF-a, tumor
necrosis factor-a; IFN-g, interferon-g; ONOO, peroxynitrite; O2
, super-
oxide; NO, nitric oxide; phox, phagocyte oxidase
* Corresponding author. Tel.: +81-52-744-2364; fax: +81-52-744-
2371.Peroxynitrite (ONOO ), the reaction product of NO and
superoxide (O2
), is more toxic than either NO or O2
 alone.
ONOO is capable of nitrating critical tyrosine residues,
which may alter protein function. For example, ONOO as
has been observed to cause the specific nitration of Tyr34 in
manganese-superoxide dismutase (MnSOD), thereby alter-
ing the function of the enzyme [4]. The release of ONOO
was increased in atherosclerosis [5], and we previously
reported that ONOO could impair the NO-mediated vas-
cular response during the regression of dietary cholesterol-
induced atherosclerosis [6].
The neutrophil protein complex NADPH oxidase plays a
vital role in the nonspecific host defense against pathogens
by generating large quantities of O2
 during the respiratory
burst [7]. NADPH oxidase is the major source of O2
 in
vascular tissues and consists of the membrane-bound heter-
odimeric flavocytochrome b558 (gp91phox and p22phox) and
four cytosolic proteins (p47phox, p67phox, p40phox andRac1/2).
These components must assemble in the membrane for the
enzyme to become active. Assembly of the complex is
regulated through the phosphorylation of p47phox [8].ed.
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estradiol on phagocyte NADPH oxidase activity and on the
protein expression of p47phox and p67phox in phorbol ester
(PMA)-differentiated human monocytic cells (THP-1 cells).Fig. 2. The inhibition of NADPH oxidase activity by 17h-estradiol. 1: 24-h
incubation with TNF-a (10 ng/ml) plus IFN-g (100 U/ml) in PMA-
differentiated THP-1 cells; 2: in the presence of 10 6 M 17h-estradiol; 3:
10 8 M 17h-estradiol; 4: 10 10 M 17h-estradiol; 5: 10 8 M 17h-estradiol
plus 10 6M ICI 182, 780 (hatched bar). Data represent the meanF S.E. of
four separate experiments (*P < 0.05 vs. lane 1).2. Materials and methods
2.1. Chemicals
17h-Estradiol, 17a-estradiol, progesterone, bis-N-meth-
ylacridinium nitrate (Lucigenin), h-nicotinamide adenine
dinucleotide phosphate, reduced form (NADPH) and phor-
bol 12-myristate 13-acetate (PMA) were purchased from
Sigma (St. Louis, MO). Testosterone was purchased from
Wako Pure Chemical (Osaka, Japan). ICI-182,780 was
kindly provided by Zeneka Pharmaceuticals. Monoclonal
p47phox and p67phox antibodies were purchased from Trans-
duction Laboratories (Lexington, KY). Human recombinant
tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g)
were purchased from Roche Diagnostics (Indianapolis, IN).
All of the other reagents and solvents used in this study
were of analytic reagent grade.
2.2. Cell culture
The human monocytic cells (THP-1 cells) were cultured
at 37 jC in a humidified atmosphere of 5% CO2 using
RPMI-1640 medium containing 10% fetal calf serum,
penicillin (100 U/ml) and streptomycin (100 Ag/ml). To
measure NADPH oxidase, we seeded onto 15-cm culture
dishes at a minimum of 6 106 cells per plate. To perform
Western blot, reverse transcription-polymerase chain reac-
tion (RT-PCR) and electrophoresis mobility shift assay
(EMSA), we seeded onto 6-cm culture dishes at a minimum
of 1106 cells per plate. In order to differentiate THP-1Fig. 1. NADPH oxidase activity in THP-1 cells. 1: nondifferentiated THP-1
cells; 2: PMA-differentiated THP-1 cells; 3: 24-h incubation with TNF-a
(10 ng/ml) plus IFN-g (100 U/ml) in PMA-differentiated THP-1 cells; 4:
supernatant of ultracentrifugation (100,000 g for 60 min); 5: without
NADPH. Data represent the meanF S.E. of three separate experiments
(*P< 0.05 vs. lane 1).cells to the macrophage-like cell, we incubated them for 48
h with 100 nM PMA in RPMI-1640 phenol red-free
medium containing 10% charcoal stripped fetal calf serum.
2.3. NADPH oxidase activity
The differentiated THP-1 cells were incubated for 24 h
in incubation medium containing indicated concentrations
of sex steroid hormones, TNF-a (10 ng/ml) and IFN-g
(100 U/ml). The activity was measured by the Lucigenin
method with chemiluminescence leader (BLR-201,
ALOKA) as previously described [9]. The protein con-
centration was determined by a Dc protein assay kit (Bio-
Rad, CA).
2.4. Western blotting
The differentiated THP-1 cells were incubated for 24 h
with the indicated concentrations of 17h-estradiol, TNF-a
(10 ng/ml) and IFN-g (100 U/ml). Ten-microgram proteins
were separated by 10% sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis and transferred to
PVDF-membrane. The blots were placed in blocking
solutions (Tris-buffered saline (10 mM Tris (pH 8.0) and
150 mM NaCl), 0.05% Tween-20 and 5% nonfat milk) for
1 h. Blots were incubated for 1 h with p47phox or p67phox
monoclonal antibodies, washed with Tris-buffered saline
and 0.05% Tween-20 and incubated with horseradish
peroxidase-conjugated secondary antibody. Bounds IgGs
were visualized using an enhanced chemiluminescence
detection system (Pierce, IL) according to the manufactur-
er’s protocol. Band intensities were quantified with the
NIH-image system.
2.5. RT-PCR
The differentiated THP-1 cells were incubated for 6 h
with the indicated concentrations of 17h-estradiol, TNF-a
Fig. 3. The effect of sex steroid hormones on the NADPH oxidase activity.
1: 24-h incubation with TNF-a (10 ng/ml) plus IFN-g (100 U/ml) in PMA-
differentiated THP-1 cells; 2: 10 8 M 17h-estradiol; 3: 10 8 M 17a-
estradiol; 4: 10 8 M testosterone; 5: 10 8 M progesterone. Data represent
the meanF S.E. of three separate experiments (*P< 0.05 vs. lane 1).
D. Sumi et al. / Biochimica et Biophy(10 ng/ml) and IFN-g (100 U/ml). Total RNA was isolated
by TRIzol reagents (Invitrogen). Total RNA, 0.5 Ag, was
reverse-transcribed to the first strand cDNA and these
cDNAs were amplified by PCR performed with One Step
RNA PCR Kit (Takara Shuzo, Otsu, Japan) using the
following primers: p47phox sense primer 5V-caccgagatctac-
gagttccata-3Vand p47phox anti-sense primer 5V-ctttcatctga-
cagaaccaccaac-3V [10] Internal control for equal cDNA
loading in each reaction was assessed using the following
primers: h-actin sense primer 5V-gacctggctggccgggacctg-
3Vand h-actin anti-sense primer 5V-cacatctgctggaaggtgga-
3V. The amplified products were resolved by 2% agarose
gel electrophoresis. Ethidium bromide-stained band inten-
sities were quantified with the NIH-image system. p47phox
band intensities were compared with band intensities of
h-actin.Fig. 4. Western blot analysis of p67phox and p47phox in THP-1 cells. The open
expression. 1: nondifferentiated THP-1 cells; 2: PMA-differentiated THP-1 cells;
cells; 4: 24-h incubation with TNF-a (10 ng/ml) plus IFN-g (100 U/ml) in PMA-d
p47phox band intensities were compared with nondifferentiated THP-1 cells (lane
vs. lane 1, yP< 0.05 vs. lane 2).2.6. EMSA
The differentiated THP-1 cells were incubated for 1.5 h
with the indicated concentrations of 17h-estradiol, TNF-a
(10 ng/ml) and IFN-g (100 U/ml). Nuclear extracts of THP-1
cells were extracted with the NE-PER nuclear extraction
reagent (Pierce). Double-stranded oligonucleotide encom-
passing the kappaB (nB) 5V-ggggatttccc-3V (Santa Cruz
Biotechnology, Inc, CA) was end-labeled using g-32P-ATP,
7000 Ci/mmol, and T4 polynucleotide kinase (Promega,
CA). Five-microgram nuclear protein extract was incubated
for 30 min at room temperature in binding buffer (25 mM
HEPES (pH 7.9), 100 mM KCl, 5% Ficoll-400, 2% glycerol,
0.025% Igepal CA-630, 0.05 mM EDTA, 0.05 mM EGTA, 2
mM DTT, 0.5 mM PMSF) containing 10-Ag bovine serum
albumin and 1-Ag polydI–dC. Radiolabeled consensus oli-
gonucleotide (100,000 cpm) was subsequently added to each
sample, and incubated at room temperature for an additional
30 min. Protein–DNA complexes were subsequently
resolved in a 5% native Tris/taurine-buffered gel. Gels were
dried and exposed to autoradiographic film at  80 jC.
2.7. Statistical analysis
Data were obtained from three or four different experi-
ments. Each value represents the meanF S.E. Statistical
significance was assessed by the Student’s t test, and differ-
ences between treatment groups were considered significant
at P < 0.05.
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To determine the effects of estrogen on NADPH oxidase
in human monocytic cells (THP-1 cells), we comparedand solid bars represent band intensities of p67phox and p47phox protein
3: 24-h incubation with TNF-a (10 ng/ml) in PMA-differentiated THP-1
ifferentiated THP-1 cells. Band intensities were calculated and p67phox and
1). Data represent the meanF S.E. of three separate experiments (*P < 0.05
Fig. 5. The effect of 17h-estradiol on p67phox and p47phox protein expression in THP-1 cells. The open and solid bars represent band intensities of p67phox and
p47phox protein expression. 1: 24-h incubation with TNF-a (10 ng/ml) plus IFN-g (100 U/ml) in PMA-differentiated THP-1 cells; 2, 3 and 4: in the presence of
10 6M (lane 2), 10 8M (lane 3) and 10 10M (lane 4) 17h-estradiol. Band intensities were calculated and p67phox or p47phox band intensities were compared with
TNF-a (10 ng/ml) plus IFN-g (100 U/ml) induced THP-1 cells (lane 1). Data represent the meanF S.E. of four separate experiments (*P< 0.05 vs. lane 1).
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differentiated THP-1 cells. Fig. 1 shows that PMA-induced
differentiation alone induced NADPH oxidase activity up to
2.2-fold. And we also detected that TNF-a (10 ng/ml) plus
IFN-g (100 U/ml) stimulated NADPH oxidase activity up to
3.5-fold in differentiated THP-1 cells compared with non-
differentiated THP-1 cells. We confirmed that this method is
adequate for measuring NADPH oxidase activity on the
ground of low activity with cytosolic fraction (100,000 g
supernatant, lane 4) substitute for membrane fraction and
reaction without NADPH (lane 5).
As shown in Fig. 2, physiological concentrations of 17h-
estradiol (10 8 and 10 10 M) inhibited NADPH oxidase
activity stimulated by TNF-a plus IFN-g in PMA-differ-
entiated THP-1 cells, but 10 6 M 17h-estradiol did not
inhibit activity and 17h-estradiol (10 8 and 10 10 M) did
not inhibit NADPH oxidase activity in the absence of TNF-
a plus IFN-g (data not shown). The estrogen receptor
antagonist ICI 182,780 abolished the inhibition of NADPH
oxidase activity by 17h-estradiol. The stereoisomer of 17h-
estradiol (17a-estradiol), testosterone and progesterone
were also tested but did not inhibit NADPH oxidase activity
(Fig. 3). These results indicate that inhibition of the NADPH
oxidase activity is specific to the action of 17h-estradiol,
and is mediated through the estrogen receptor.Fig. 6. The effect of 17h-estradiol on p47phox mRNA expression in THP-1 cells
differentiated THP-1 cells; 2, 3 and 4: in the presence of 10 6M (lane 2), 10 8M
were calculated with h-actin band intensities and compared with TNF-a (10 ng/m
meanF S.E. of three separate experiments (*P< 0.05 vs. lane 1).Considering that 17h-estradiol was shown to inhibit
NADPH oxidase activity, we examined the expression of
two components of NADPH oxidase, p47phox and p67phox.
We examined p47phox and p67phox protein expression in the
effects of differentiation and cytokine treatment. As shown
in Fig. 4, p47phox protein expression is enhanced 2.7-fold by
PMA-induced differentiation, 3.8-fold by the presence of
TNF-a, and 6.8-fold by the presence of TNF-a plus IFN-g
in comparison with nondifferentiated THP-1 cells. In con-
trast, p67phox protein expression was stimulated by differ-
entiation, but not further enhanced by TNF-a or TNF-a plus
IFN-g.
As shown in Fig. 5, 17h-estradiol (10 8 and 10 10 M)
significantly attenuates the up-regulation of p47phox protein
expression caused by TNF-a plus IFN-g. In correlation with
inhibition of NADPH oxidase activity, 10 6 M 17h-estra-
diol did not attenuate p47phox expression. Moreover, 17h-
estradiol did not affect p67phox protein expression.
In order to determine whether the effect of 17h-estradiol
on p47phox expression is correlated with changes in p47phox
mRNA expression, we performed RT-PCR analysis (Fig. 6).
The p47phox mRNA levels were up-regulated by differ-
entiation, and further up-regulated by TNF-a plus IFN-g
in comparison to undifferentiated cells (data not shown). As
with protein expression, 17h-estradiol (10 8 and 10 10 M). 1: 6-h incubation of TNF-a (10 ng/ml) plus IFN-g (100 U/ml) in PMA-
(lane 3) and 10 10M (lane 4) 17h-estradiol. p47phox mRNA band intensities
l) plus IFN-g (100 U/ml) induced THP-1 cells (lane 1). Data represent the
Fig. 7. The effect of 17h-estradiol on TNF-a plus IFN-g mediated NF-nB
nuclear translocation in THP-1 cells. 1: no stimulation; 2: 1.5-h incubation
of TNF-a (10 ng/ml) plus IFN-g (100 U/ml); 3, 4 and 5: in the presence of
10 6M (lane 3), 10 8M (lane 4) and 10 10M (lane 5) 17h-estradiol.
Specific DNA-binding complexes of NF-nB were identified using 100-fold
excess of cold oligonucleotide competitor in the binding assay (lane 6). The
arrow indicates the specific DNA–protein complex.
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induced by TNF-a plus IFN-g.
In order to clarify that 17h-estradiol inhibits p47phox
expression resulted from an inhibition of NF-nB activation,
we examined an EMSA. As shown in Fig. 7, EMSA
revealed that shifted band intensities were decreased with
10 8 M (lane 4) and 10 10 M 17h-estradiol (lane 5)
treatment compared with TNF-a plus IFN-g (lane 2). These
data confirm that 17h-estradiol inhibits p47phox expression
through the inhibition of NF-nB activation induced by TNF-
a plus IFN-g.4. Discussion
Premenopousal women have a lower risk of cardiovas-
cular disease than age-matched males. Postmenopausal
women exhibit a significant increase in risk due to the loss
of circulating estrogen [11]. It has been suggested that
estrogen possesses anti-atherosclerotic effects. We have
observed that a physiological concentration of 17h-estradiol
retards the progression of rabbit atherosclerosis induced by
high-cholesterol diets and balloon catheter injury [12].
However, the cellular and molecular mechanisms by which
17h-estradiol has its effect are still unclear. On the other
hand, it has been shown that O2
 production was increased
in an atherosclerotic aorta induced by a high cholesterol
diet. NADPH oxidase appears to be an important source of
O2
 in vascular vessels, as has been suggested by experi-
ments on the NADPH oxidase knockout mouse [13] or
using novel competitive inhibitor of NADPH oxidase [14].
We detected p47phox-positive staining in macrophages of
rabbit atherosclerotic lesions (unpublished data). The pur-
pose of this study was to examine the effects of 17h-estradiol on NADPH oxidase activity and expression in
human monocytic cells, namely THP-1 cells, in an attempt
to provide further insight into the anti-atherosclerotic
effects.
First, we observed that NADPH oxidase activity in THP-1
cells induced differentiation with PMA that is higher than
that in nondifferentiated THP-1 cells. It has been shown that
monocytes invade the area between the endothelium and
smooth muscle cells and are differentiated to macrophages
[15], and that reactive oxygen species from the macrophage
will cause the progression of atherosclerosis mediated by
reduction of the nitric oxide half-life [16] or the stimulation
of adhesion molecule expression [17]. Taken together with
our data, a large quantity of O2
 from macrophages that
differentiate from monocytes in atherosclerotic lesions is
produced by activated NADPH oxidase and this O2
 repre-
sents an important step in the development of atherosclerosis.
We investigated whether 17h-estradiol inhibits NADPH
oxidase activity in the presence of TNF-a plus IFN-g,
whose expression has been reported in atherosclerotic
lesions [18]. We have shown that, as one of the anti-
atherosclerotic effects of estrogen through the role of NO,
the effects of estrogen on the stimulation of eNOS expres-
sion [19] and the prevention of eNOS mRNA destabilization
induced by TNF-a will cause an increase in the release of
nitric oxide from endothelial cells [20]. This study shows
that the effects of 17h-estradiol on the inhibition of NADPH
oxidase activity prolong the NO half-life, and may thus
partially protect against the development of atherosclerosis.
It is expected that the production of ONOO and nitro-
tyrosine is inhibited through the inhibition of NADPH
oxidase activity by 17h-estradiol. However, we could not
detect a decrease in nitrotyrosine in MnSOD caused by 17h-
estradiol using the immunoprecipitation technique because
we could not detect any accumulation of NO stimulated by
TNF-a plus IFN-g. This finding was supported by the fact
that there was no inducible NO metabolites stimulated by
lipopolysaccharide (LPS) plus IFN-g, although the induci-
ble nitric oxide synthase (iNOS) mRNA expression was
detected in human monocytes [21]. Recently it has been
suggested that a nitrite-dependent peroxidase reaction rather
than ONOO may cause the production of nitrotyrosine in
activated macrophages, but this reaction has not been shown
in THP-1 cells [22].
In our study of the effects of 17h-estradiol on the
inhibition of NADPH oxidase activity, we focused on the
regulation of p47phox and p67phox expression. Our results
show that TNF-a plus IFN-g induces p47phox protein and
mRNA expression, but not p67phox. THP-1 cells have well
characterized TNF-a and IFN-g receptors. These data are in
agreement with previous reports that have shown that
p47phox expression is induced in cytokine-differentiated
THP-1 cells through the regulation of transcription [23]
and that p47phox expression is up-regulated by IFN-g in
purified monocytes from chronic granulomatous disease
patients [24]. Additionally, these monocytes did not up-
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of transcription, we have shown that 17h-estradiol inhibits
the iNOS expression that is stimulated by LPS plus IFN-g in
the J774 mouse macrophage cell line [25].
The data presented here show that 17h-estradiol inhibits
NF-nB activation caused by TNF-a plus IFN-g. In 1996,
Caulin-Glaser et al. [26] reported that 17h-estradiol
inhibited the endothelial cell adhesion molecule expression
(E-selectin, ICAM-1 and VCAM-1) induced by interleukin-
1 in endothelial cells. This report suggested that 17h-
estradiol can modulate NF-nB nuclear translocation, DNA
binding or transactivation. Recently, 17h-estradiol was
reported to inhibit NF-nB activation by increasing NF-nB
p105 levels [27]. We are still uncertain that up-regulation of
p105 levels is involved in inhibition of p47phox expression
by 17h-estradiol.
Wagner et al. [28] recently reported that 17h-estradiol
inhibits constitutive NADPH oxidase (gp91phox) expression
in human endothelial cells. NADPH oxidase is the principal
source of O2
 in endothelial cells [29] and plays a critical
role in the development of atherosclerosis [30]. It is possible
that 17h-estradiol also inhibits inducible gp91phox expres-
sion. However, this remains to be investigated.
In the present study, the effects of three different concen-
trations of 17h-estradiol on NADPH oxidase activity and
expression were evaluated. The results indicate that 10 8 and
10 10 M 17h-estradiol inhibited NADPH oxidase activity
and p47phox expression induced by TNF-a plus IFN-g;
however, a higher concentration of 17h-estradiol (10 6 M)
did not produce these inhibitory effects. A biphasic response
to 17h-estradiol has been previously reported for endothelial
cell adhesion, proliferation and hepatic cholesterol metabo-
lism [31,32]. We speculate that higher concentrations of 17h-
estradiol (z 10 6 M) negatively affect estrogen receptor
expression and thereby reduce estrogen responsiveness in
THP-1 cells. In endothelial cells, 10 7 M 17h-estradiol was
tested, and reported to be more effective than 10 9 M 17h-
estradiol in inhibiting constitutive gp91phox expression [28].
The lack of a biphasic effect in this circumstance may be
related to differences between endothelial and monocytic
cells, such as the regulation of estrogen receptor expression,
and possibly the cytokines tested.
In the present study, we have demonstrated that 17h-
estradiol inhibits NADPH oxidase activity induced by
TNF-a plus IFN-g in PMA-differentiated THP-1 cells, at
least in part by regulation of p47phox expression through the
NF-nB inhibition. This effect was specific to 17h-estradiol
and the estrogen receptor-mediated system. This mechanism
of estrogen action may be clinically relevant to postmeno-
pausal women patients suffering from cardiovascular disease.Acknowledgements
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